ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer.
Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R.
Nat Rev Clin Oncol. 2015 Oct;12(10):573-83. doi: 10.1038/nrclinonc.2015.117. Epub 2015 Jun 30.
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.
Valabrega G, Montemurro F, Aglietta M.
Ann Oncol. 2007 Jun;18(6):977-84. doi: 10.1093/annonc/mdl475. Epub 2007 Jan 17.
IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis.
Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, Verstegen NJM, Ciampricotti M, Hawinkels LJAC, Jonkers J, de Visser KE.
Nature. 2015 Jun 18;522(7556):345-348. doi: 10.1038/nature14282. Epub 2015 Mar 30.
Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination.
Huh HD, Sub Y, Oh J, Kim YE, Lee JY, Kim HR, Lee S, Lee H, Pak S, Amos SE, Vahala D, Park JH, Shin JE, Park SY, Kim HS, Roh YH, Lee HW, Guan KL, Choi YS, Jeong J, Choi J, Roe JS, Gee HY, Park HW.
Mol Cancer. 2023 Mar 30;22(1):63. doi: 10.1186/s12943-023-01753-7.
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role.
Lloyd MR, Wander SA, Hamilton E, Razavi P, Bardia A.
Ther Adv Med Oncol. 2022 Jul 30;14:17588359221113694. doi: 10.1177/17588359221113694. eCollection 2022.
USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors.
Lim KS, Li H, Roberts EA, Gaudiano EF, Clairmont C, Sambel LA, Ponnienselvan K, Liu JC, Yang C, Kozono D, Parmar K, Yusufzai T, Zheng N, D'Andrea AD.
Mol Cell. 2018 Dec 20;72(6):925-941.e4. doi: 10.1016/j.molcel.2018.10.045.
Mechanism of Bazhen decoction in the treatment of colorectal cancer based on network pharmacology, molecular docking, and experimental validation.
Lu S, Sun X, Zhou Z, Tang H, Xiao R, Lv Q, Wang B, Qu J, Yu J, Sun F, Deng Z, Tian Y, Li C, Yang Z, Yang P, Rao B.
Front Immunol. 2023 Sep 20;14:1235575. doi: 10.3389/fimmu.2023.1235575. eCollection 2023.
Conducive target range of breast cancer: Hypoxic tumor microenvironment.
Cheng W, Xiao X, Liao Y, Cao Q, Wang C, Li X, Jia Y.
Front Oncol. 2022 Sep 26;12:978276. doi: 10.3389/fonc.2022.978276. eCollection 2022.
Identification of circulating metabolites linked to the risk of breast cancer: a mendelian randomization study.
Zhu X, Huang H, Zou M, Luo H, Liu T, Zhu S, Ye B.
Front Pharmacol. 2024 Sep 11;15:1442723. doi: 10.3389/fphar.2024.1442723. eCollection 2024.
Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.
Serrano García L, Jávega B, Llombart Cussac A, Gión M, Pérez-García JM, Cortés J, Fernández-Murga ML.
Front Immunol. 2024 Dec 13;15:1513421. doi: 10.3389/fimmu.2024.1513421. eCollection 2024.
